Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Cocrystal says eligible to receive up to $156M in payments, royalties from Merck » 11:28
07/10/20
07/10
11:28
07/10/20
11:28
MRK

Merck

$76.83 /

+0.125 (+0.16%)

, COCP

Cocrystal Pharma

$2.03 /

+0.2 (+10.93%)

In presentation slides,…

In presentation slides, Cocrystal Pharma (COCP) said it has recognized revenue of $6.56M in 2019 and is "eligible to receive up to $156 million in milestone payments and royalties (undisclosed) on product sales" from its exclusive license and collaboration agreement with Merck (MRK) to discover and develop certain proprietary influenza A/B antiviral agents. In the same presentation slides, Cocrystal said it is "aggressively pursuing" development of novel antiviral therapies for the treatment of COVID-19 infections and gave an update on its planned next steps. Reference Link

ShowHide Related Items >><<
MRK Merck
$76.83 /

+0.125 (+0.16%)

COCP Cocrystal Pharma
$2.03 /

+0.2 (+10.93%)

MRK Merck
$76.83 /

+0.125 (+0.16%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
COCP Cocrystal Pharma
$2.03 /

+0.2 (+10.93%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 H.C. Wainwright
Cocrystal Pharma initiated with a Buy at H.C. Wainwright
06/16/20 Noble Capital
Cocrystal Pharma initiated with an Outperform at Noble Capital
MRK Merck
$76.83 /

+0.125 (+0.16%)

  • 31
    Oct
MRK Merck
$76.83 /

+0.125 (+0.16%)

MRK Merck
$76.83 /

+0.125 (+0.16%)

MRK Merck
$76.83 /

+0.125 (+0.16%)

Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 10:18
07/10/20
07/10
10:18
07/10/20
10:18
ABEO

Abeona Therapeutics

$3.02 /

-0.33 (-9.85%)

, AMGN

Amgen

$247.24 /

-4.025 (-1.60%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$86.61 /

-0.71 (-0.81%)

, PFE

Pfizer

$33.69 /

+0.24 (+0.72%)

, SNY

Sanofi

$50.25 /

-0.31 (-0.61%)

, VRCA

Verrica Pharmaceuticals

$9.70 /

+0.94 (+10.73%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$247.24 /

-4.025 (-1.60%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.69 /

+0.24 (+0.72%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

  • 20
    Dec
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

Recommendations
Pacira price target raised to $69 from $53 at Jefferies » 07:41
07/10/20
07/10
07:41
07/10/20
07:41
PCRX

Pacira

$57.65 /

+1.11 (+1.96%)

, JNJ

Johnson & Johnson

$142.46 /

-0.78 (-0.54%)

Jefferies analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PCRX Pacira
$57.65 /

+1.11 (+1.96%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

PCRX Pacira
$57.65 /

+1.11 (+1.96%)

07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
06/30/20 SVB Leerink
Pacira price target raised to $58 from $45 at SVB Leerink
JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
PCRX Pacira
$57.65 /

+1.11 (+1.96%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

PCRX Pacira
$57.65 /

+1.11 (+1.96%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

Conference/Events
International Aids Society to hold a virtual conference » 04:55
07/10/20
07/10
04:55
07/10/20
04:55
ABT

Abbott

$93.68 /

+1.11 (+1.20%)

, BDX

Becton Dickinson

$258.57 /

+5.92 (+2.34%)

, GILD

Gilead

$74.67 /

-0.96 (-1.27%)

, HOLX

Hologic

$57.45 /

-0.13 (-0.23%)

, MRK

Merck

$76.70 /

-1.17 (-1.50%)

, OSUR

OraSure

$13.86 /

+0.495 (+3.71%)

23rd International AIDS…

23rd International AIDS Virtual Conference: AIDS 2020 will be held on July 6-10. Webcast Link

ShowHide Related Items >><<
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
GILD Gilead
$74.67 /

-0.96 (-1.27%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
HOLX Hologic
$57.45 /

-0.13 (-0.23%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$76.70 /

-1.17 (-1.50%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

  • 03
    Jun
  • 21
    May
MRK Merck
$76.70 /

-1.17 (-1.50%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

Yesterday
Hot Stocks
Merck Animal Health gets FDA approval of Bravecto Monthly Chews » 16:31
07/09/20
07/09
16:31
07/09/20
16:31
MRK

Merck

$76.70 /

-1.17 (-1.50%)

Merck Animal Health…

Merck Animal Health announced the FDA's approval of BRAVECTO 1-MONTH Chews for dogs and puppies 8 weeks of age and older. The product is administered as a single, monthly flavored chew formulation for treatment and prevention of fleas and treatment and control of ticks. BRAVECTO 1-MONTH is expected to be available in the coming months.

ShowHide Related Items >><<
MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

Periodicals
Telecom Italia declines to invite Huawei to 5G equipment tender, Reuters says » 15:38
07/09/20
07/09
15:38
07/09/20
15:38
TIAOF

Telecom Italia

$0.00 /

+ (+0.00%)

, CSCO

Cisco

$46.84 /

+1.02 (+2.23%)

, ERIC

Ericsson

$9.38 /

-0.165 (-1.73%)

, NOK

Nokia

$4.20 /

+0.035 (+0.84%)

, MSFT

Microsoft

$213.95 /

+1.06 (+0.50%)

, MU

Micron

$50.13 /

+0.42 (+0.84%)

, WDC

Western Digital

$42.51 /

-0.28 (-0.65%)

, ACIA

Acacia Communications

$67.70 /

+0.31 (+0.46%)

, NPTN

NeoPhotonics

$8.78 /

+0.18 (+2.09%)

, LITE

Lumentum

$84.09 /

+1.93 (+2.35%)

, IIVI

II-VI

$44.22 /

+1.11 (+2.57%)

Telecom Italia (TIAOF)…

Telecom Italia (TIAOF) has not invited Huawei to take part in a tender to supply 5G equipment for the core network it is readying to create in Italy and Brazil, Reuters' Elvira Pollina reports, citing two sources familiar with the matter. The list of suppliers invited to take part in the tender includes Cisco (CSCO), Ericsson (ERIC), Nokia (NOK), Mavenir, and Affirmed Networks, which was recently acquired by Microsoft (MSFT), Pollina says, citing one of the two sources. Huawei suppliers include Micron Technology (MU) and Western Digital (WDC), while makers of optical components, including Acacia Communications (ACIA), NeoPhotonics (NPTN), Lumentum (LITE), and Finisar (IIVI), have previously reacted negatively to headlines regarding U.S. enforcement actions and allegations against China's Huawei. Reference Link

ShowHide Related Items >><<
WDC Western Digital
$42.51 /

-0.28 (-0.65%)

TIAOF Telecom Italia
$0.00 /

+ (+0.00%)

NPTN NeoPhotonics
$8.78 /

+0.18 (+2.09%)

NOK Nokia
$4.20 /

+0.035 (+0.84%)

MU Micron
$50.13 /

+0.42 (+0.84%)

MSFT Microsoft
$213.95 /

+1.06 (+0.50%)

LITE Lumentum
$84.09 /

+1.93 (+2.35%)

IIVI II-VI
$44.22 /

+1.11 (+2.57%)

ERIC Ericsson
$9.38 /

-0.165 (-1.73%)

CSCO Cisco
$46.84 /

+1.02 (+2.23%)

ACIA Acacia Communications
$67.70 /

+0.31 (+0.46%)

TIAOF Telecom Italia
$0.00 /

+ (+0.00%)

06/24/20 Goldman Sachs
Telecom Italia reinstated with a Sell at Goldman Sachs
06/11/20 JPMorgan
Telecom Italia downgraded to Neutral on estimate risk at JPMorgan
06/11/20 JPMorgan
Telecom Italia downgraded to Neutral from Overweight at JPMorgan
03/11/20 JPMorgan
JPMorgan maintains Overweight on Telecom Italia after Q4 results
CSCO Cisco
$46.84 /

+1.02 (+2.23%)

07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Morgan Stanley
Morgan Stanley upgrades Cisco to Overweight with discount to S&P at 10-year high
07/09/20 Morgan Stanley
Cisco upgraded to Overweight from Equal Weight at Morgan Stanley
07/02/20 JPMorgan
JPMorgan sees attractive opportunities in India for Cisco, Ciena
ERIC Ericsson
$9.38 /

-0.165 (-1.73%)

04/17/20 Credit Suisse
Ericsson price target raised to SEK 98 from SEK 97 at Credit Suisse
03/30/20 BofA
US 1 List changes at BofA
03/30/20 Cowen
Ericsson upgraded to Outperform from Market Perform at Cowen
03/27/20 Raymond James
Raymond James upgrades Ericsson with networking an essential service
NOK Nokia
$4.20 /

+0.035 (+0.84%)

07/08/20 JPMorgan
Nokia downgraded to Neutral from Overweight at JPMorgan
07/06/20 Rosenblatt
Samsung on track to replace Nokia as 5G RAN supplier at Verizon, says Rosenblatt
06/25/20 Deutsche Bank
Nokia price target raised to EUR 4.80 from EUR 4 at Deutsche Bank
06/01/20 JPMorgan
JPMorgan upgrades Nokia to Overweight with 5G cycle 'just starting'
MSFT Microsoft
$213.95 /

+1.06 (+0.50%)

07/09/20 Morgan Stanley
Microsoft price target raised to $230 from $198 at Morgan Stanley
07/09/20 Wedbush
Microsoft price target raised to $260 from $220 at Wedbush
07/07/20 Loop Capital
Logitech price target raised to $78 from $58 at Loop Capital
07/06/20 Morgan Stanley
Microsoft skilling focus tempers some Pluralsight optimism, says Morgan Stanley
MU Micron
$50.13 /

+0.42 (+0.84%)

06/30/20 RBC Capital
Micron price target raised to $60 from $55 at RBC Capital
06/30/20 Morgan Stanley
Morgan Stanley would add to Micron positions on weakness in coming 'rough patch'
06/30/20 Raymond James
Micron price target raised to $65 from $60 at Raymond James
06/30/20 Mizuho
Micron price target raised to $63 from $60 at Mizuho
WDC Western Digital
$42.51 /

-0.28 (-0.65%)

06/30/20 Benchmark
Micron report and guidance 'bode well' for Western Digital, says Benchmark
06/26/20 KeyBanc
Memory supply remains limited in 2H amid low visibility, says KeyBanc
06/22/20 Benchmark
Western Digital upgraded to Buy from Hold at Benchmark
06/19/20 Benchmark
Benchmark says Samsung's NAND chip issues likely positive for HDD makers
ACIA Acacia Communications
$67.70 /

+0.31 (+0.46%)

09/23/19 Northland
Inphi drops after Northland sees 'large cut' to Amazon 400G rollout plans
07/18/19 JPMorgan
JPMorgan boosts Ciena target to $53, sees further share upside
07/16/19 Rosenblatt
Acacia Communications downgraded to Neutral from Buy at Rosenblatt
07/11/19 MKM Partners
Ciena investment case is strengthening, says MKM Partners
NPTN NeoPhotonics
$8.78 /

+0.18 (+2.09%)

06/16/20 B. Riley FBR
NeoPhotonics downgraded to Neutral on Huawei risks at B. Riley FBR
06/16/20 B. Riley FBR
NeoPhotonics downgraded to Neutral from Buy at B. Riley FBR
05/21/20 Rosenblatt
Rosenblatt sees little impact on Lumentum, NeoPhotonics' current sales to Huawei
05/01/20 Northland
NeoPhotonics price target raised to $13 from $9.75 at Northland
LITE Lumentum
$84.09 /

+1.93 (+2.35%)

07/02/20 MKM Partners
Lumentum price target raised to $107 from $96 at MKM Partners
05/06/20 Craig-Hallum
Lumentum price target raised to $100 from $95 at Craig-Hallum
05/06/20 Piper Sandler
Lumentum price target raised to $100 from $95 at Piper Sandler
IIVI II-VI
$44.22 /

+1.11 (+2.57%)

07/06/20 JPMorgan
II-VI shares offer 25% upside potential, says JPMorgan
07/01/20 Susquehanna
II-VI price target raised to $54 from $50 at Susquehanna
06/09/20 Needham
II-VI price target raised to $57 from $52 at Needham
05/12/20 Deutsche Bank
II-VI price target raised to $50 from $35 at Deutsche Bank
WDC Western Digital
$42.51 /

-0.28 (-0.65%)

NPTN NeoPhotonics
$8.78 /

+0.18 (+2.09%)

NOK Nokia
$4.20 /

+0.035 (+0.84%)

MU Micron
$50.13 /

+0.42 (+0.84%)

MSFT Microsoft
$213.95 /

+1.06 (+0.50%)

LITE Lumentum
$84.09 /

+1.93 (+2.35%)

IIVI II-VI
$44.22 /

+1.11 (+2.57%)

ERIC Ericsson
$9.38 /

-0.165 (-1.73%)

CSCO Cisco
$46.84 /

+1.02 (+2.23%)

ACIA Acacia Communications
$67.70 /

+0.31 (+0.46%)

  • 02
    Jul
WDC Western Digital
$42.51 /

-0.28 (-0.65%)

TIAOF Telecom Italia
$0.00 /

+ (+0.00%)

NOK Nokia
$4.20 /

+0.035 (+0.84%)

MU Micron
$50.13 /

+0.42 (+0.84%)

MSFT Microsoft
$213.95 /

+1.06 (+0.50%)

ERIC Ericsson
$9.38 /

-0.165 (-1.73%)

CSCO Cisco
$46.84 /

+1.02 (+2.23%)

WDC Western Digital
$42.51 /

-0.28 (-0.65%)

NPTN NeoPhotonics
$8.78 /

+0.18 (+2.09%)

NOK Nokia
$4.20 /

+0.035 (+0.84%)

MU Micron
$50.13 /

+0.42 (+0.84%)

MSFT Microsoft
$213.95 /

+1.06 (+0.50%)

LITE Lumentum
$84.09 /

+1.93 (+2.35%)

IIVI II-VI
$44.22 /

+1.11 (+2.57%)

ERIC Ericsson
$9.38 /

-0.165 (-1.73%)

CSCO Cisco
$46.84 /

+1.02 (+2.23%)

ACIA Acacia Communications
$67.70 /

+0.31 (+0.46%)

WDC Western Digital
$42.51 /

-0.28 (-0.65%)

NOK Nokia
$4.20 /

+0.035 (+0.84%)

MU Micron
$50.13 /

+0.42 (+0.84%)

MSFT Microsoft
$213.95 /

+1.06 (+0.50%)

LITE Lumentum
$84.09 /

+1.93 (+2.35%)

ERIC Ericsson
$9.38 /

-0.165 (-1.73%)

CSCO Cisco
$46.84 /

+1.02 (+2.23%)

MSFT Microsoft
$213.95 /

+1.06 (+0.50%)

Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Pfizer (PFE) announced earlier it has pledged $100M to the new Antimicrobial Resistance, or "AMR," Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. "The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development," the company stated. "As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis," added Pfizer Chairman and CEO Albert Bourla. Other investors in the AMR Action Fund include Amgen (AMGN), Bayer (BAYRY), Roche (RHHBY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Merck (MRK), Merck KGaA (MKGAY), Teva (TEVA), Takeda Pharmaceutical (TAK), Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Novartis (NVS). Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

Periodicals
White House finalizing federal ban for firms using Huawei, others, Reuters says » 13:03
07/09/20
07/09
13:03
07/09/20
13:03
IIVI

II-VI

$43.80 /

+0.69 (+1.60%)

, LITE

Lumentum

$83.68 /

+1.52 (+1.85%)

, NPTN

NeoPhotonics

$8.79 /

+0.185 (+2.15%)

, ACIA

Acacia Communications

$67.67 /

+0.28 (+0.42%)

, WDC

Western Digital

$41.83 /

-0.96 (-2.24%)

, MU

Micron

$49.40 /

-0.315 (-0.63%)

, ZTCOY

ZTE Corp.

$0.00 /

+ (+0.00%)

The Trump administration…

The Trump administration intends to finalize regulations this week that will prohibit the U.S. government from purchasing goods or services from any company that uses products from five Chinese companies, including Huawei, Hikvision, and Dahua, Reuters' David Shepardson reports, citing a U.S. official. The rule could have wide-ranging implications for companies that sell goods and services to the U.S. government, since they will now have to certify that they do not use goods from Dahu and Hikvision, even though both are among the top sellers of surveillance equipment and cameras globally, Shepardson says. The same rules would apply to two-way radios from Hytera Communications, as well as telecoms equipment company ZTE Corp. (ZTCOY), Shepardson notes. Huawei suppliers include Micron Technology (MU) and Western Digital (WDC), while makers of optical components, including Acacia Communications (ACIA), NeoPhotonics (NPTN), Lumentum (LITE), and Finisar (IIVI), have previously reacted negatively to headlines regarding U.S. enforcement actions and allegations against China's Huawei. Reference Link

ShowHide Related Items >><<
ZTCOY ZTE Corp.
$0.00 /

+ (+0.00%)

WDC Western Digital
$41.83 /

-0.96 (-2.24%)

NPTN NeoPhotonics
$8.79 /

+0.185 (+2.15%)

MU Micron
$49.40 /

-0.315 (-0.63%)

LITE Lumentum
$83.68 /

+1.52 (+1.85%)

IIVI II-VI
$43.80 /

+0.69 (+1.60%)

ACIA Acacia Communications
$67.67 /

+0.28 (+0.42%)

IIVI II-VI
$43.80 /

+0.69 (+1.60%)

07/06/20 JPMorgan
II-VI shares offer 25% upside potential, says JPMorgan
07/01/20 Susquehanna
II-VI price target raised to $54 from $50 at Susquehanna
06/09/20 Needham
II-VI price target raised to $57 from $52 at Needham
05/12/20 Deutsche Bank
II-VI price target raised to $50 from $35 at Deutsche Bank
LITE Lumentum
$83.68 /

+1.52 (+1.85%)

07/02/20 MKM Partners
Lumentum price target raised to $107 from $96 at MKM Partners
05/21/20 Rosenblatt
Rosenblatt sees little impact on Lumentum, NeoPhotonics' current sales to Huawei
05/06/20 Craig-Hallum
Lumentum price target raised to $100 from $95 at Craig-Hallum
05/06/20 Piper Sandler
Lumentum price target raised to $100 from $95 at Piper Sandler
NPTN NeoPhotonics
$8.79 /

+0.185 (+2.15%)

06/16/20 B. Riley FBR
NeoPhotonics downgraded to Neutral on Huawei risks at B. Riley FBR
06/16/20 B. Riley FBR
NeoPhotonics downgraded to Neutral from Buy at B. Riley FBR
05/01/20 Northland
NeoPhotonics price target raised to $13 from $9.75 at Northland
ACIA Acacia Communications
$67.67 /

+0.28 (+0.42%)

09/23/19 Northland
Inphi drops after Northland sees 'large cut' to Amazon 400G rollout plans
07/18/19 JPMorgan
JPMorgan boosts Ciena target to $53, sees further share upside
07/16/19 Rosenblatt
Acacia Communications downgraded to Neutral from Buy at Rosenblatt
07/11/19 MKM Partners
Ciena investment case is strengthening, says MKM Partners
WDC Western Digital
$41.83 /

-0.96 (-2.24%)

06/30/20 Benchmark
Micron report and guidance 'bode well' for Western Digital, says Benchmark
06/26/20 KeyBanc
Memory supply remains limited in 2H amid low visibility, says KeyBanc
06/22/20 Benchmark
Western Digital upgraded to Buy from Hold at Benchmark
06/19/20 Benchmark
Benchmark says Samsung's NAND chip issues likely positive for HDD makers
MU Micron
$49.40 /

-0.315 (-0.63%)

06/30/20 RBC Capital
Micron price target raised to $60 from $55 at RBC Capital
06/30/20 Morgan Stanley
Morgan Stanley would add to Micron positions on weakness in coming 'rough patch'
06/30/20 Raymond James
Micron price target raised to $65 from $60 at Raymond James
06/30/20 Mizuho
Micron price target raised to $63 from $60 at Mizuho
ZTCOY ZTE Corp.
$0.00 /

+ (+0.00%)

07/02/20 Roth Capital
USF ban for Huawei, ZTE should benefit Cambium, says Roth Capital
02/18/20 Goldman Sachs
ZTE Corp. downgraded to Neutral from Buy at Goldman Sachs
12/03/19 Rosenblatt
Lumentum, Maxim, Macom to benefit from ZTE, Huawei procurement, says Rosenblatt
11/05/19 Rosenblatt
Applied Optoelectronics upgraded to Buy ahead of guidance at Rosenblatt
WDC Western Digital
$41.83 /

-0.96 (-2.24%)

NPTN NeoPhotonics
$8.79 /

+0.185 (+2.15%)

MU Micron
$49.40 /

-0.315 (-0.63%)

LITE Lumentum
$83.68 /

+1.52 (+1.85%)

IIVI II-VI
$43.80 /

+0.69 (+1.60%)

ACIA Acacia Communications
$67.67 /

+0.28 (+0.42%)

  • 02
    Jul
ZTCOY ZTE Corp.
$0.00 /

+ (+0.00%)

WDC Western Digital
$41.83 /

-0.96 (-2.24%)

MU Micron
$49.40 /

-0.315 (-0.63%)

IIVI II-VI
$43.80 /

+0.69 (+1.60%)

ZTCOY ZTE Corp.
$0.00 /

+ (+0.00%)

WDC Western Digital
$41.83 /

-0.96 (-2.24%)

NPTN NeoPhotonics
$8.79 /

+0.185 (+2.15%)

MU Micron
$49.40 /

-0.315 (-0.63%)

LITE Lumentum
$83.68 /

+1.52 (+1.85%)

IIVI II-VI
$43.80 /

+0.69 (+1.60%)

ACIA Acacia Communications
$67.67 /

+0.28 (+0.42%)

WDC Western Digital
$41.83 /

-0.96 (-2.24%)

MU Micron
$49.40 /

-0.315 (-0.63%)

LITE Lumentum
$83.68 /

+1.52 (+1.85%)

Hot Stocks
Moderna enters collaboration with ROVI » 08:10
07/09/20
07/09
08:10
07/09/20
08:10
MRNA

Moderna

$61.54 /

+0.46 (+0.75%)

Moderna and Laboratorios…

Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna's mRNA vaccine candidate against COVID-19 (mRNA-1273) at ROVI's facility in Madrid, Spain. The companies said in a release, "As part of the agreement, ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labeling to support production of hundreds of millions of doses of the vaccine candidate intended in principle to supply markets outside of the U.S. starting in early 2021. ROVI will also hire additional staffing required to support manufacturing operations and production."

ShowHide Related Items >><<
MRNA Moderna
$61.54 /

+0.46 (+0.75%)

MRNA Moderna
$61.54 /

+0.46 (+0.75%)

07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
MRNA Moderna
$61.54 /

+0.46 (+0.75%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$61.54 /

+0.46 (+0.75%)

MRNA Moderna
$61.54 /

+0.46 (+0.75%)

MRNA Moderna
$61.54 /

+0.46 (+0.75%)

Hot Stocks
Kymera Therapeutics, Sanofi enter strategic collaboration » 07:02
07/09/20
07/09
07:02
07/09/20
07:02
SNY

Sanofi

$51.54 /

+0.14 (+0.27%)

Kymera Therapeutics…

Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150M in cash upfront and may receive more than $2B in potential development, regulatory and sales milestones, as well as significant royalty payments. Kymera retains the option to participate in U.S. development and commercialization for both programs. This includes the ability to participate equally in the costs, profits and losses after opt-in, and to co-promote partnered products in the U.S. Under terms of the collaboration, Sanofi will make an upfront payment of $150M in cash to Kymera for global rights to develop its small molecule IRAK4 protein degraders in inflammation and immunology indications, and a second earlier stage undisclosed program. IRAK4 is believed to play a key role in multiple immune-inflammatory diseases, including hidradenitis suppurativa, atopic dermatitis and rheumatoid arthritis. Kymera will advance the IRAK4 program through Phase 1 clinical trials; Sanofi will assume clinical development and commercialization responsibilities thereafter. Sanofi will lead all clinical development activities for the second program. Kymera will have the option to participate in the development of both programs in the US during clinical development. Kymera will retain global rights to its IRAK4 program in oncology indications.

ShowHide Related Items >><<
SNY Sanofi
$51.54 /

+0.14 (+0.27%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
SNY Sanofi
$51.54 /

+0.14 (+0.27%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.